Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

被引：0

作者：

Casneuf, Tineke ^{[1
]}

Lysaght, Andrew ^{[2
]}

LeFave, Clare ^{[3
]}

Bald, Jaime ^{[4
]}

Weiss, Brendan ^{[5
,6
]}

van de Donk, Niels W. C. J. ^{[7
]}

Lokhorst, Henk M. ^{[7
]}

Ahmadi, Tahamtan ^{[4
]}

Sasser, A. Kate ^{[4
]}

机构：

[1] Janssen Res & Dev, Beerse, Belgium

[2] Immuneering Corp, Cambridge, MA USA

[3] LabConnect LLC, Seattle, WA USA

[4] Janssen Res & Dev LLC, Spring House, PA USA

[5] Univ Penn, Dept Med, Div Hematol & Oncol, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[6] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[7] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] DARATUMUMAB IN MONOTHERAPY AND COMBINATION AS TREATMENT IN RELAPSED / REFRACTORY MULTIPLE MYELOMA: EXPERIENCE OF A THIRD LEVEL HOSPITAL
Auria Caballero, C.
Gamarro Calvo, S.
De Poo Rodriguez, M., V
Martinez Fernandez, R.
Sanchez Quinones, B.
Dourdil Sahun, M., V
Bonafonte Arruga, E.
Alcacera Lopez, A.
Palomera Bernal, L.
HAEMATOLOGICA, 2018, 103 : 124 - 124
[42] Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
Shackleton, Louisa
Fay, James
Smyth, Elizabeth
Murphy, Philip
Glavey, Siobhan
Quinn, John
EJHAEM, 2020, 1 (01): : 312 - 314
[43] INTERFERENCES IN THE SCREENING OF IRREGULAR ANTIBODIES IN 4 PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB
Ramirez Patricia, Garcia
Montserrat, Olcoz
Montserrat, Alvarellos
Ma Cruz, Montoya
Pamela, Millacoy
Jose Maria, Arguinano
Ma Piva, Sanchez
Saioa, Zalba
Ma Victoria, Aznar
Ma Luisa, Antelo
Itziar, Ezpeleta
HAEMATOLOGICA, 2016, 101 : 275 - 276
[44] HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH MULTIPLE MYELOMA (MM) TREATED WITH DARATUMUMAB. EXPERIENCE IN A CENTER
Gonzalo, Benzo
Beatriz, Aguado
Isabel, Vicuna
Carlota, Mayor
Ana, Puchol
Sofia, Diaz
Carmen, Jimenez-Montes
Ahlam, Serroukh
Adrian, Alegre
HAEMATOLOGICA, 2021, 106 (10) : 139 - 139
[45] Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
Husnain, Muhammad
Kurtin, Sandra
Barkett, Nikki
bin Riaz, Irbaz
Agarwal, Amit
CASE REPORTS IN ONCOLOGICAL MEDICINE, 2016, 2016
[46] PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB IN COMBINATION. EXPERIENCE IN SINGLE CENTER
Robredo Rodriguez, B.
Villanueva Jimenez, P.
Quesada Sanz, M.
Sanchez Garcia, M., I
Delgado Mateos, F.
Avila Alvarez, J. R.
Casaus Garcia, A.
HAEMATOLOGICA, 2019, 104 : 397 - 397
[47] The safety of daratumumab for the treatment of multiple myeloma
Cejalvo, Maria J.
Ribas, Paz
de la Rubia, Javier
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 753 - 760
[48] Daratumumab improves survival in multiple myeloma
Baker, Holly
LANCET ONCOLOGY, 2016, 17 (11): : E480 - E480
[49] Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, Antonio
Chanan-Khan, Asher
Weisel, Katja
Nooka, Ajay K.
Masszi, Tamas
Beksac, Meral
Spicka, Ivan
Hungria, Vania
Munder, Markus
Mateos, Maria V.
Mark, Tomer M.
Qi, Ming
Schecter, Jordan
Amin, Himal
Qin, Xiang
Deraedt, William
Ahmadi, Tahamtan
Spencer, Andrew
Sonneveld, Pieter
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08): : 754 - 766
[50] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Dimopoulos, M. A.
Oriol, A.
Nahi, H.
San-Miguel, J.
Bahlis, N. J.
Usmani, S. Z.
Rabin, N.
Orlowski, R. Z.
Komarnicki, M.
Suzuki, K.
Plesner, T.
Yoon, S. -S.
Ben Yehuda, D.
Richardson, P. G.
Goldschmidt, H.
Reece, D.
Lisby, S.
Khokhar, N. Z.
O'Rourke, L.
Chiu, C.
Qin, X.
Guckert, M.
Ahmadi, T.
Moreau, P.
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14): : 1319 - 1331

← 1 2 3 4 5 →